Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases

The Long Run with Luke Timmerman by The Long Run with Luke Timmerman

Mar 3, 202601:05:45Science & Medicine

Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.

Related Episodes

Continue listening to more episodes from The Long Run with Luke Timmerman.

Sep 9, 2026 - 01:36:12

Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide mole...

Aug 25, 2026 - 01:07:17

Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus...

Aug 11, 2026 - 01:17:31

Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs base...

Jul 28, 2026 - 01:07:17

Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung dise...

Jul 14, 2026 - 01:08:18

Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to bette...

Jun 30, 2026 - 01:07:27

Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cance...

Jun 16, 2026 - 01:11:43

Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to cor...

Jun 2, 2026 - 01:08:12

Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reim...